Grb7 Upregulation Is a Molecular Adaptation to HER2 Signaling Inhibition Due to Removal of Akt-Mediated Gene Repression

The efficacy of anti-HER2 therapeutics, such as lapatinib and trastuzumab, is limited by primary and acquired resistance. Cellular adaptations that allow breast cancer cell to survive prolonged HER2 inhibition include de-repression of the transcription factor FOXO3A with consequent estrogen receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Nencioni, Alessio, Cea, Michele, Garuti, Anna, Passalacqua, Mario, Raffaghello, Lizzia, Soncini, Debora, Moran, Eva, Zoppoli, Gabriele, Pistoia, Vito, Patrone, Franco, Ballestrero, Alberto
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814867/
https://www.ncbi.nlm.nih.gov/pubmed/20126311
http://dx.doi.org/10.1371/journal.pone.0009024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814867/
https://www.ncbi.nlm.nih.gov/pubmed/20126311
http://dx.doi.org/10.1371/journal.pone.0009024

Ejemplares similares